Skip to main content
MenuSearch & Directory

Research Innovation Group

The Research Innovation Group (RIG) manages the intellectual property portfolio and industry contracting activities for Saint Louis University.

RIG’s mission is to increase the adoption and dissemination of SLU research discoveries and intellectual properties and to leverage SLU research and innovation assets to benefit the community. Our goal is to become exceptional at technology transfer and industry engagement as well as a partner of choice for research and intellectual property commercialization.

RIG’s main office is located in the heart of the Cortex Innovation Community to better connect with industry and integrate SLU within the region’s innovation and entrepreneurship ecosystem. The Cortex Innovation Community was founded in 2002 through a collaboration among SLU, Washington University in Saint Louis, University of Missouri – St. Louis, BJC Healthcare, and the Missouri Botanical Garden. It is the Midwest’s premier innovation hub for research, development, and commercialization in biosciences and technology. Cortex anchors the St. Louis region’s growing innovation ecosystem for startups and established companies.

For SLU Students

The Research Innovation Group at Saint Louis University offers support and encouragement to student entrepreneurship, innovation, and research excellence in a variety of ways. All current students are very welcome to contact us if you have any questions.

MedLaunch

MEDLaunch is a non-profit biomedical and entrepreneurship incubator partnering with Saint Louis University and other organizations in the Saint Louis area. The goal of MedLaunch is to improve the standard of healthcare through the engineering and design of creative solutions while also fostering a community of entrepreneurship and collaboration at Saint Louis University.

Visit the MedLaunch Website

For Community Stakeholders

The Research Innovation Group at Saint Louis University is committed to leveraging our research and innovation assets for the benefit of our community. We strive to generate real impact in tackling social and scientific challenges facing our society through partnerships and programs.

The September 2017 Reinventing Research Commercialization Conference

The Research Innovation Group is committed to developing and implementing new approaches to technology transfer. It knows these will be needed to bring transformative discoveries resulting from university research more quickly and effectively to market. To this end, in September 2017, the Research Innovation Group brought together national leaders in technology transfer, regional innovators, entrepreneurs, business managers and advisors at the "Reinventing Research Commercialization Conference" to participate in this reinvention process.

The presentations from this conference are available below.

For Industry

Saint Louis University strives to be a partner of choice for university research and intellectual property commercialization. Please contact us if you would like to discuss specific technologies or other opportunities to collaborate with us.

 

Technology Transfer Fellows Program

The Technology Transfer Fellows Program aims to help individuals develop translational research and lean innovation skills through experiential learning; expose individuals, particularly those from underrepresented groups, to the field of technology transfer; and facilitate the dissemination and adoption of Saint Louis University research discoveries and technologies.

Participants in the program can receive up to $2,000 per project while working to advance the transfer of Saint Louis University technologies to the private sector to benefit the public interest.  They do so by using the SLUStart I-Corps curriculum to validate commercialization concepts for SLU technologies under the guidance of SLUStart I-Corps instructors.  After successfully completing these initial validation efforts, they can apply to the NSF I-Corps National Teams program to continue working on the project.  If accepted, they can receive a stipend of $15,000 while working to further advance the technology towards commercialization.

Individuals interested in participating in the Technology Transfer Fellows Program may apply online at any time.  The program is operated by the Research Innovation Group within the Office of the Vice President for Research at Saint Louis University.  Please contact Malcolm Townes by phone at 314-977-1633 or by email at malcolm.townes@slu.edu if you have any questions.

Apply Now

Who can participate in the Technology Transfer Fellows Program? 

Anyone who meets the following requirements can participate in the Technology Transfer Fellows Program:

  • Individuals at least 18 years of age.
  • Eligible to work in the United States (if not a student or employee of Saint Louis University).

Participation in the program is at the sole and absolute discretion of Saint Louis University.  In addition to faculty, staff, postdoctoral researchers, graduate students, and undergraduate students at Saint Louis University, non-SLU affiliated individuals may also participate in the program. 
 
Participation in the Technology Transfer Fellows Program is not meant to replace a person's current employment.  Individuals are expected to participate in the program in adjunct to their normal jobs. 

How do I apply?
To apply, simply submit the online application.
Can individuals outside of the St. Louis, Missouri area participate in the program? 
Yes, individuals outside of the St. Louis, Missouri area are welcomed to participate in the program. 
What do participants in the Technology Transfer Fellows Program do? 

Technology Transfer Fellows participate in the SLUStart I-Corps program to advance the transfer of specific Saint Louis University technologies to the private sector to benefit the public interest.  This includes completing at least 15 customer discovery interviews per project and documenting a venture thesis for a technology. The primary tasks are as follows: 

  • Task 1: Participate in an initial SLUStart I-Corps cohort working session.
  • Task 2: Participate in a second SLUStart I-Corps cohort working session. 
  • Task 3: Complete and document up to 15 customer discovery interviews and document the  venture thesis according to program standards.

For individuals who are outside of the St. Louis, Missouri area, we can make special arrangements if necessary to facilitate their participation in the SLUStart I-Corps cohort sessions (i.e., Task 1 and Task 2). 

What technologies can fellows work on for their project?

With approval from the program manager, Technology Transfer Fellows can work on any technology for which Saint Louis University has received an intellectual property disclosure that is not less than 60 days old, has accepted assignment of the technology, and is actively pursuing commercialization.

Are fellows allowed to work on more than one project? 

Fellows may work on multiple projects during their participation only if invited to do so.  However, they may only work on one project at a time.  Once a participant completes a project, the program manager will evaluate the participants work and deliverables.  If the deliverables are satisfactory, the program manager may invite the fellow to perform additional work on the project or work on a different project. 

Do fellows work on projects individually or in teams? 

Fellows may work on projects either individually or in teams of two with the approval of the program manager.  Each person in a two-person team will be responsible for conducting at least seven (7) customer discovery interviews.

How does the program work? 

Technology Transfer Fellows receive funds disbursements at a fixed flat rate of $133 per properly documented customer discovery interview up to a maximum of 15 interviews per project.  Fellows have a limited amount of time to complete a project (typically about two months). 

After completing the SLUStart I-Corps program and conducting at least 15 customer discovery interviews for a project, the fellow can form a team (i.e., recruit a technical lead and industry mentor) and apply to the NSF I-Corps National Teams program to continue working on the project.  The fellow will serve as entrepreneurial lead for the team.  If accepted, the fellow can receive a stipend of $15,000 while participating in additional training and conducting additional customer discovery interviews.

What time commitment is required to participate in the program? 

The two working sessions (i.e., SLUStart I-Corps cohort sessions) typically last about three  to four hours each. The meeting days and times for the cohort working sessions are scheduled according the availability of the cohort participants. In many cases, cohort sessions are scheduled on weekends or weekday evenings for the convenience of participants.  
 
Additionally, fellows are expected to spend time outside of the working sessions applying what they've learned to conduct customer discovery interviews for their assigned SLU technologies. However, exactly how much time a participant spends outside of the working sessions is at their discretion and will vary from project to project. The amount of time it takes to conduct each customer discovery interview is typically about 30 minutes but this varies to some degree. This does not include the time required to recruit and schedule an interview participant.

What is a venture thesis? 
A venture thesis is simply a concise statement outlining the value that a technology or new venture is believed to offer to a specific customer segment or user population. It has a specific structure designed to capture essential information about the technology application or solution, customer segment or user population, job-to-be-done from the perspective of the customer or user, and value proposition. To see an example of a venture thesis, visit https://www.cognitoforms.com/SaintLouisUniversityResearchInnovationGroup/SLUStartICorpsDeliverableReport.
Can fellows continue to pursue commercialization of a technology on their own once they've completed their project? 
If a fellow decides that they want to continue pursuing commercialization of the technology on their own once they've completed their project, they are welcomed to negotiate a license for the technology. 

 

Search Intellectual Property Portfolio

Use the directory below to browse and search our intellectual property portfolio to identify technologies that may be of interest to you.

ID Intellectual Property Type
ID Intellectual Property Type
98-002 Facilitating Research to Develop Treatments for Hemochromatosis Research Tool
98-013 NK3.3 Human Natural Killer Cell Line Derived from Healthy Male Research Tool
03-016 Studying Oncolytic Adenovirus Vectors Using a Syrian Hamster Model Research Tool
03-017 Studying Oncolytic Adenovirus Vectors Using a Cotton Rat Model Research Tool
04-011 Studying Lymphangiogensis-related Immunoresponse to Tumor Cells Research Tool
07-006 Screening for Anti-Adenovirus Agents in Immunosuppressed Individuals Research Tool
07-017 Characterizing an Individual's Risk of Developing Cardiovascular Disease Diagnostic
07-023 Minimizing Risks and Complications Associated with Retinal Detachment Surgery Medical Device
10-001 Improving Weather-Influenced Decisions Using Environmental Predictive Analytics Industrial Application
10-010 Developing an Antiviral Vaccine for Herpes Simplex Virus by Encoding Co-stimulation Molecules Therapeutic
10-014 Improving Robotic Systems for Brain Surgery Using a Self-Opening Distractor Medical Device
10-015 Improving Operating Room Procedures Using a Finger-based Data Input Device Medical Device
10-017 Detecting DNA and RNA Using Biolayer Interferometry with Ultra-High Sensitivity Diagnostic
10-018 Preventing and Treating Influenza Using Peptides to Induce Heterosubtypic Influenza T Cell Responses Therapeutic
10-024 Inexpensively Diagnosing Sickel Cell Disease Under Conditions with Poor Technological Infrastructure Diagnostic
10-034 Detecting and Quantifying Specific Proteins in Biological and Environmental Samples Diagnostic
11-003 Developing Therapies for Various Diseases Such as Fibrosis, Dermal Scarring, Retinal Disease, Cancers, and Viral Infections Therapeutic
11-010 Studying Chronic Liver Disease Using a PiZ Transgenic Mouse Model of a1At Mutant Z Liver Injury Research Tool
11-013 Testing for Inherited Metabolic Diseases Diagnostic
11-015 Novel Approach for Treating Cancer Using Adenovirus E1A Fragments Drug Delivery
11-018 Plasmid Expressing Human Carbonic Anhydrase IV  Research Tool
11-027 Treating Cornelia de Lange Syndrome Using Indomethacin-based Drugs Therapeutic
11-033 Preventing Breakage of Electrodes Placed in the Brain to Treat Movement Disorders and Compulsive Disorders Medical Device
11-034 Treating Diseases With Pathologies Promoted by Angiogensis Therapeutic
12-001 Curing Hepatitis B Infections Using a Therapy that Suppresses HBV Replication Therapeutic
12-012 Treating Type I Diabetes Using a Therapy That Targets C-peptide Research Tool
12-013 Preventing Bone Loss by Regulating FOXP3+CD8 T Cells Therapeutic
12-014 Treating Malaria Using Aminohydantoin Compounds Therapeutic
12-019 Measuring HbF in Blood Inexpensively Diagnostic
13-014 Microfluidic Device Systems and Methods for Fabrication Industrial Application
13-018 Inexpensively Predicting Weather Threats With High Spatial and Temporal Resolution Industrial Application
13-019 Treating Facioscapulohumeral Muscular Dystrophy (FSHD) Therapeutic
13-026 Preventing and Treating Herpesvirus Infections from Strains Resistant to Anti-Herpesvirus Drugs Therapeutic
14-012 Treating Chronic Neuropathic Pain Therapeutic
14-013 Delivering Bioactive Components Using a Hydrolytically Degradable Polyethylene Glycol Microsphere Drug Delivery
14-016 Treating Protein C Deficiency Diagnostic
14-017 Diagnosing and Treating Endometriosis-related Infertility Therapeutic
14-018 Novel Therapeutic Strategy for Treating Human Breast Cancer Regulating SALL1 Functions Therapeutic
15-004 Developing Therapies for Various Diseases Such as Fibrosis, Dermal Scarring, Retinal Disease, Cancers, and Viral Infections Therapeutic
15-005 Diagnosing Halogen Gas Exposure and Eosinophil-driven Diseases Diagnostic
15-008 Preventing and Treating Chagas Disease Research Tool
15-012 Producting Biomaterial Platforms for Researching Cell Substrate Relationships Industrial Application
15-014 Treating Cancers, Neurodegenerative Diseases, and Other Rare Conditions Using MUB LBL and LBL-based Peptides Drug Delivery
15-016 Preventing and Treating Herpes Infections Therapeutic
15-017 Preventing and Treating Herpes and Hepatitis Viral Infections Therapeutic
15-032 Promoting Nerve Repair Using Neural Tissue Engineering Method of Transferring Single-Walled Carbon Nanotubes on a Hydrogel Drug Delivery
15-036 Curing Cancer by Unmasking Tumors from the Immune System Therapeutic
16-001 Minimizing the Duration and Toxicity of Treatments for Infections Caused by the Fungal Pathogen Cryptococcus neoformans Therapeutic
16-004 Treating Coagulation Disorders Without Bleeding Side Effects Therapeutic
16-006 Integrating 3-Dimensional Cell Culture Scaffolds in Microfluidic Devices Industrial Application
16-011 Preventing and Treating Infections Caused by Herpesviridae Using Mutant Herpes Simplex Virus Therapeutic
16-018 Producing Nanomaterials Using Mask-free Production Methods Industrial Application
16-019 Providing Immunity Against Divergent Strains of Influenza Therapeutic
16-021 Minimizing the Cost and Time Requirements for Hematopoietic Stem Cell Therapy (HSCT) Therapeutic
16-023 Minimizing Inflammation While Treating Fibrosis Therapeutic
17-002 Novel Antibiotic Candidates Based on Inhibitors of Nucleotidyltransferase Superfamily Enzymes Therapeutic
17-003 Deriving Photoinduced Ring Closure From Dinaphthothiphenes Industrial Application
17-004 Treating Cancers and Infectious Diseases Using NK3.3-Derived Extracellular Vesicles Therapeutic
17-007 Measuring GPER Agonism, Antagonism, and Inverse Agonism Using a Novel High-Throughput Screening Assay Diagnostic
17-008 Maintaining GALNS Enzyme Activity for Extended Periods Using an Injectable Hydrogel Depot Drug Delivery
17-010 Regenerating Tissue Using an Aligned Electrospun Matrix of Decellularized Muscle Therapeutic
17-013 Treating Atherosclerosis by Induction of TcREG Therapeutic
17-015 Treating Short Gut Syndrome and Preventing Necrotizing Enterocolitis Using Fatty Acid Conjugated Epidermal Growth Factor Variants Therapeutic
17-017 Treating Facioscapulohumeral Muscular Dystrophy (FSHD) Using P38 Inhibitors Therapeutic
17-024 Measuring the Efficiency of Efflux Pumps in Bacterial Strains and Permeability Properties of Bacterial Cell Envelopes Using a Molecular Fluorescent Ruler Diagnostic
17-026 Treating Muscle Dysfunction Using ERR Ligands Therapeutic
17-029 Simplifying the Simultaneous Analysis of Multiple Samples Using Mass Spectrometry Research Tool
17-033 Developing More Effective Treatments for Malaria Using Pyrrolidine Compounds Therapeutic
17-034 Assessing Biofilm Infections Using a Novel Bacterial Biofilm Assay Diagnostic
17-036 Treating Malaria Using Novel Clinical Drug Candidates that Exhibit Oral Efficacy with Once Daily Dosing Therapeutic
17-037 Dibenzothiophene Sulfone Cell Dyes Research Tool
17-039 Treating Cancer with Photodynamic Therapy Using Novel Molecules that Induce Apoptosis Drug Delivery
17-040 Improving Cognitive Function in Aging-related Dementia Using Adropun Peptides Therapeutic
18-002 Developing Treatments for Diseases Associated With the CLIC1 Gene Research Tool
18-003 Using Photo-Deoxygenation Induced Apoptosis to Treat Cancer Therapeutic
18-010 Identifying GPER Agonists with Superior Selectivity Research Tool
18-020 Treating Zika Virus Using Selective Estrogen Modulators Therapeutic
18-023 Treating Facioscapulohumeral Muscular Dystrophy (FSHD) Using Pyrrolopyridinone Compounds that Inhibit BET Bromodomains Therapeutic
18-024 Improving the Consistency of Image-guided Head and Neck Radiotherapy Delivery Using an Auto-adaptable Head Rest Medical Device
18-026 Generating Atomic Oxygen Using Visible Light Drug Delivery
18-027 Developing a Functional Cure for Hepatitis B Therapeutic
18-028 Enabling High Precision, Low Cost Deuterium-Based Universal Metabolomic Isotope Labeling Research Tool
19-001 Developing New Types of Molecules for Fluorescent Microsopy Research Tool
19-006 Simplifying the Analysis of Chimerism Data Research Tool
19-007 Detecting Exposure to Specific Pathogens and Agents Diagnostic
19-010 Improving Tumor Immunotherapy by Reprogramming Lipid Metabolism Therapeutic
19-011 Delivering Medicines in a Controlled Manner Over an Extended Period of Time Using Degradable Hydrogels Drug Delivery
19-012 Generating Proteins for High-Throughput Drug Screening Using Customized Plasmids for Expressing Nuclear Receptor Proteins in E. Coli Therapeutic
19-014 Using GCNF Ligands to Increase the Efficacy of Cancer Therapeutics Therapeutic
19-015 Using a Novel Mechanism to Treat MRSA Infections and Tuberculosis Therapeutic
19-017 Improving Telepathology Medical Device
19-019 Treating and Preventing Neuropathic Pain Using Novel Non-Narcotic Analgesics Therapeutic
19-020 Treating Neurological Diseases, Autoimmune Disorders, and Muscular Disorders Using Rev-erb Modulators Therapeutic
19-021 Improving the X-Ray Imaging of the Vasculature of Biological Systems Diagnostic
19-027 Treating Frontotemporal Dementia Therapeutic
19-028 Improving DNA Sequencing Diagnostics
19-029 Treating Traumatic Brain Injuries Therapeutic
19-033 Preventing Rift Valley Fever in Humans Therapeutic
20-001 Creating Exhibitions of Annotated Collections Industrial Application
20-003  Treating Diarrhea in Transplant Patients, AIDS Patients, and Children Therapeutic
20-009 Treating Drug Resistant BRCA-deficient Tumors Therapeutic
20-018 Minimizing the Risks Associated with Supraphysiologic Iron that is Added to Infant Formulas to Offset Poor Iron Absorption Therapeutic
20-019 Evaluating a Variety of Therapeutics for Liver Disease with Robust Internal Control Research Tool
20-022 Diagnosing and Preventing Leukemias That Affect Both Adults and Children Research Tool
20-025 Minimizing Compliance Problems with Type 1 Diabetes Treatment Therapeutic
20-026 Treating Neuropathic Pain with Greater Selectivity Therapeutic
21-003 Minimizing Errors When Treating Diabetes Mellitus with Severe Hyperglycemia or Ketoacidosis Diagnostic
21-004 Facilitating Research to Develop Treatments for HFE-associated Hereditary Hemochromatosis Research Tool
21-008 Treating Neuropathic Pain Therapeutic
21-011 Treating Triple Negative Breast Cancer and Endocrine-Resistant Cancer Therapeutic
21-012 Authenticating Users in a Secure and Non-Intrusive Manner Industrial Application
21-014 Designing Components and Devices with Physical and Electrical Characteristics Not Attainable with Currently Available Materials Industrial Application
22-001 Treating Neurodegenerative Disorders Linked to TDP-43 Pathology Therapeutic
22-008 Maximizing the Yield of Plants and Crops Industrial Application
22-009 Increasing the Yield of Plants and Crops Industrial Application
22-018 Improving the Effectiveness of Drug Screening Research Tools
22-020 Increasing the Efficacy of Cancer Immunotherapy Thereapeutics
22-026 Improving the Efficacy of Immunotherapy Therapeutics
22-027 Developing Treatments for Head and Neck Squamous Cell Carcinoma Research Tools
22-030 Mitigating Liver and Gut Injury Associated with Short Gut Syndrome Medical Devices
23-001 Studying Rare Liver Diseases Research Tools
23-002 Preventing Mycobacterium Tuberculosis Therapeutics
23-003 Reducing the Mortality of Invasive Fungal Infections  Therapeutics